Video

Dr Melinda Magyari Explains the Treatment Landscape for Pediatric-Onset MS

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explains the treatment paradigm for pediatric-onset multiple sclerosis (MS).

Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explains the treatment paradigm for pediatric-onset multiple sclerosis (MS).

Transcript

What does the treatment paradigm for pediatric MS look like today?

That's a good question, but we have the recommendation from the international multiple sclerosis group that disease-modifying treatment should be initiated in children with MS. Of course, the benefit/risk should be also taken into consideration, so the treatment paradigm in most of the countries is escalation therapy, starting with a mild, moderately effective drug in mild and moderate diseases activity. But I see in our registry and also in others that children with highly active disease are initiated with more effective therapies.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Merrill H. Stewart, MD
Nicolas Ferreyros, managing director, Community Oncology Alliance
Dr Ibrahim Aldoss
Jody Agena, PharmD, MBA, director of pharamcy operations, Virginia Cancer Specialists
Rachel Rohaidy, MD
Mansi Shah, MD
Miriam Freimer, MD
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Dr Pankit Vachhani
Dr Ibrahim Aldoss
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo